---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-22-000108"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:43:35.858557+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Context reports preliminary Phase 2 data for ONA-XR: 4-month PFS rate of 44% in metastatic breast cancer

## Summary
- 4-month progression-free survival (PFS) rate of 44% in ER+, HER2- metastatic breast cancer patients in SMILE trial.
- ONA-XR combined with fulvestrant showed favorable safety and tolerability in second- or third-line setting.
- Previously disclosed endometrial cancer data showed 4-month PFS rate of 77% with anastrozole combination.
- ELONA Phase 1b/2 trial combining ONA-XR with elacestrant; Phase 1b data expected Q4 2023.

## SEC filing metadata
- accession: 0001842952-22-000108
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000108/0001842952-22-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000108/cntx-20221207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-22-000108
- JSON: https://secwatch.observer/filing/0001842952-22-000108.json
- Plain text: https://secwatch.observer/filing/0001842952-22-000108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.